10-Q: Celcuity Inc. Reports Q1 2025 Results, Highlights Clinical Trial Progress

Celcuity Inc. announces its Q1 2025 financial results and provides updates on its ongoing clinical trials, including the expected timing of topline data for VIKTORIA-1 and CELC-G-201.

Summary

• Celcuity Inc. reported a net loss of $37.0 million for the three months ended March 31, 2025, compared to a net loss of $21.6 million for the same period in 2024.
• Research and development expenses increased to $32.2 million from $20.6 million year-over-year, driven by increased employee and consulting expenses and costs supporting ongoing clinical trials.
• General and administrative expenses rose to $3.9 million from $1.8 million year-over-year, due to increased employee and consulting expenses, professional fees, and infrastructure expansion.
• The company's cash and cash equivalents and short-term investments totaled $205.7 million as of March 31, 2025.
• Celcuity expects topline data from the PIK3CA WT cohort of the VIKTORIA-1 Phase 3 clinical trial in the third quarter of 2025 and from the PIK3CA MT cohort in the fourth quarter of 2025.
• The first patient in the VIKTORIA-2 Phase 3 clinical trial is expected to be dosed in the second quarter of 2025.
• Topline data for the Phase 1b portion of the CELC-G-201 trial is expected late in the second quarter of 2025.
• An investor exercised 695,650 warrants in March 2025, generating $5.6 million in cash.
• The company believes its current capital resources will fund clinical development program activities through 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress on its clinical trials, the increased net loss and expenses are concerning. The company has enough cash to continue operations for the foreseeable future.

Positives

• The company has sufficient capital to fund its clinical development program activities through 2026.
• The VIKTORIA-1 Phase 3 clinical trial is progressing, with topline data expected in the near term.
• The VIKTORIA-2 Phase 3 clinical trial is advancing, with the first patient expected to be dosed in Q2 2025.
• The CELC-G-201 Phase 1b/2 clinical trial is underway, with topline data expected late in Q2 2025.
• The company secured $5.6 million in cash through warrant exercises in March 2025.

Negatives

• The company's net loss increased significantly in Q1 2025 compared to Q1 2024.
• Research and development expenses and general and administrative expenses increased substantially.
• The company has an accumulated deficit of approximately $308.9 million as of March 31, 2025.

Risks

• The company is subject to risks common to companies in the development stage, including the clinical and commercial success of its initial drug product, gedatolisib, the regulatory approval of gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.
• Changes to trade policy, including new or increased tariffs and changing import and export regulations, could have a material adverse effect on our business, results of operations and financial condition.
• Disruptions at the FDA, and other government agencies from funding cuts, personnel losses, leadership changes, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.

Future Outlook

The company expects topline data from the VIKTORIA-1 Phase 3 clinical trial's PIK3CA WT cohort in Q3 2025 and from the PIK3CA MT cohort in Q4 2025. The first patient in the VIKTORIA-2 Phase 3 clinical trial is expected to be dosed in Q2 2025. Topline data for the Phase 1b portion of the CELC-G-201 trial is expected late in Q2 2025. The company believes its current capital resources will fund clinical development program activities through 2026.

Management Comments

• If gedatolisib ultimately does receive FDA approval for both the PIK3CA WT and MT populations, we estimate the peak revenue potential for this second-line indication could exceed $2 billion with just 40% market penetration.

Industry Context

The announcement highlights Celcuity's focus on developing targeted therapies for solid tumors, particularly breast cancer and prostate cancer, which aligns with the broader industry trend of personalized medicine and precision oncology. The company's lead candidate, gedatolisib, targets the PI3K/AKT/mTOR pathway, a well-validated pathway in cancer, and its clinical trials are designed to evaluate its efficacy in combination with other standard-of-care treatments.

Comparison to Industry Standards

• Celcuity is developing gedatolisib, a PI3K/mTOR inhibitor, for HR+/HER2advanced breast cancer.
• A comparable drug is PIQRAY, an oral p110-specific inhibitor, which in its Phase 3 pivotal trial, induced a Grade 3 or 4 adverse event (AE) related to hyperglycemia in 39% of patients evaluated.
• In addition, 26% of patients discontinued alpelisib due to treatment related AEs.
• By contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and less than 9% discontinued treatment.

Stakeholder Impact

• Shareholders: The increased net loss may negatively impact shareholder value in the short term, but progress in clinical trials could provide long-term benefits.
• Employees: Continued funding and clinical trial progress provide job security and potential for career advancement.
• Patients: Successful clinical trials and potential FDA approval of gedatolisib could provide new treatment options for cancer patients.

Next Steps

• The company expects topline data from the PIK3CA WT cohort of the VIKTORIA-1 Phase 3 clinical trial in Q3 2025 and from the PIK3CA MT cohort in Q4 2025.
• The first patient in the VIKTORIA-2 Phase 3 clinical trial is expected to be dosed in Q2 2025.
• Topline data for the Phase 1b portion of the CELC-G-201 trial is expected late in Q2 2025.

Key Dates

Keywords

gedatolisib, clinical trials, VIKTORIA-1, VIKTORIA-2, CELC-G-201, HR+/HER2breast cancer, mCRPC, PI3K/mTOR inhibitor, research and development, financial results